Compare Dollar Tree, Inc. (DLTR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs TransMedics Group Inc — how do they compare? Dollar Tree, Inc. trades at $118.64 (market cap $22.26B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Dollar Tree, Inc. is far larger — about 8.1× TransMedics Group Inc's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and TransMedics Group Inc for 24 Days on average.
| DLTR | TMDX | |
|---|---|---|
Market Cap | $22.26B | $2.74B |
Volume | 2,317,428 | 949,331 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $150.42 |
52-Week Low | $86.80 | $61.99 |
Typical Hold Time | 58 Days | 24 Days |
Enterprise Value | $28.87B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $118.62, up 1.99% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 45.87% ROE and trades at a reasonable P/E of 14.54. Recent news highlights strategic initiatives and store expansions driving growth, while net cash flow improved to $754 million in 2025. Analysts maintain a buy consensus with a $139.33 price target, indicating potential upside from current levels.
Outlook is positive due to earnings momentum and value-focused strategy, but risks include margin pressure from tariffs and rising costs. The stock offers growth potential if execution continues, though investors should monitor competitive pressures and economic sensitivity. Institutional buying supports confidence, but volatility near resistance at $120 requires caution.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
